Adagio Therapeutics, Inc. (ADGI) experiences an amazing incline of 31.41% in the premarket. However, the last trading session closed at $25.12 with an increase of 34.12%.
Omicron SARS-CoV-2 variant – What’s up?
On 29th November 2021, ADGI gave details on the ability of its leading SARS-CoV-2 antibody, ADG20. This will help combat the Omicron SARS-CoV-2 mutant and other recognized variations of concern. ADG20 is an experimental monoclonal antibody (mAb) product candidate with wide and powerful neutralizing activity against SARS-CoV-2.
What’s next?
The COVID-19 pandemic’s worldwide magnitude has raised immunological strain on the virus. This is leading to the generation of variants with mutations linked with an escape from typical classes of neutralizing antibodies. Unlike many other antibodies presently offered under EUA, ADG20 has also been shown to attack an epitope that is evolutionarily conserved.
Moreover, ADGI predicts ADG20 to continue efficacy against Omicron, as they have found in-vitro models with all other variants of concern reported before, due to the extremely conserved and immunorecessive character of the epitope recognized by ADG20. Furthermore, no changes in the Omicron variant’s spike protein have been linked to ADG20 neutralization resistance.
Expansion of Management Team by ADGI – Worth it?
On 22nd November 2021, ADGI announced that Jill Andersen, Redonda Miller, and Ellen Marram are a new addition to the team. Ms. Andersen comes to Adagio from Oyster Point Pharma, where she was general attorney, corporate secretary, and chief compliance officer. Ms. Andersen has experience in product design, marketing authorization, and sales, as well as product releases in a variety of therapeutic areas. Since 2016, Dr. Miller has led The Johns Hopkins Hospital as president, advancing the hospital’s commitment to providing great clinical services.
Ms. Marram, who formerly served as the presiding director of The New York Times. She was the CEO of Tropicana Beverage Group and Nabisco Biscuit Business and served on numerous private company boards as a managing director or advisor to various private equity companies, focusing on health-related consumer brands. Lastly, she is presently the chair of Newman’s Own Inc, a food company that donates 100% of its income to charitable organizations.
Ms. Andersen has experience in product innovation, marketing authorization, and sales. She has also worked in corporate administration, securities, business transactions, intellectual property, litigation, and inspections.
